TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia (any subtype) or schizoaffective disorder (any subtype)~* Treatment with clozapine for at least 1 year~* Stable dose of clozapine for at least 1 month~* Well established compliance with outpatient medications~* Female participants of non-childbearing potential or of childbearing potential and willing to practice appropriate birth control methods (complete abstinence from sexual intercourse, female sterilization, sterilization of male partner, implants of levonorgestrel, injectable progestogen, oral contraceptives, intrauterine devices, or double barrier methods of contraception using spermicide with either a condom or diaphragm) during the study~Exclusion Criteria:~* Current substance abuse~* Psychiatrically unstable~* Significant medical illness, including severe cardiovascular, hepatic, or renal disease~* History of immunosuppression~* Current or recent radiation or chemotherapy treatment for cancer~* Chronic use of steroids~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will take aripiprazole 15mg/day for 8 weeks.
- 2 (Type: PLACEBO_COMPARATOR): Participants will take placebo for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~Healthy male and female subjects~Exclusion criteria:~Any relevant deviation from healthy conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 12.5 mg empagliflozin/850 mg metformin (Type: EXPERIMENTAL): 24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/850 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 850 mg metformin tablets single dose in randomized order
- 5 mg empagliflozin/850 mg metformin (Type: EXPERIMENTAL): 24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/850 mg metformin and single Empagliflozin(5mg) and metformin (850mg) tablets single dose in randomized order
- 12.5 mg empagliflozin/500 mg metformin (Type: EXPERIMENTAL): 24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/500 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 500 mg metformin tablets single dose in randomized order
- 5 mg empagliflozin/500 mg metformin (Type: EXPERIMENTAL): 24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/500 mg metformin and single Empagliflozin(5mg) and metformin (500mg) tablets single dose in randomized order

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Participants (Part 1 only)~  * Males 18 to 45 to years of age~ * Baseline left ventricular ejection fraction (LVEF) greater than (\>) 60 percent (%)~* HER2-Positive Females (Parts 1 and 2)~  * Females greater than or equal to (≥) 18 years of age~ * Eastern Cooperative Oncology Group (ECOG) performance status of 0~ * Previous non-metastatic operable primary invasive HER2-positive breast cancer~ * Baseline LVEF \>55%~Exclusion Criteria:~* Healthy Participants (Part 1 only)~  * Clinically significant abnormalities in laboratory test results or electrocardiogram~ * History of significant allergies, gastrointestinal, renal, hepatic, cardiovascular, or pulmonary disease~ * History of hypersensitivity or allergic reaction, spontaneous or following drug administration~ * History of cardiac conditions~* HER2-Positive Females (Parts 1 and 2)~  * Metastatic disease~ * Concurrent other malignancy requiring therapy of any modality which may interfere with PK investigations or result in unexpected toxicity~ * Use of Herceptin in previous 5 months~ * Serious cardiac illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Part 1: Cohort 1 (Type: EXPERIMENTAL): Healthy male participants will receive Herceptin 6 mg/kg IV on Day 1.
- Part 1: Cohort 2 (Type: EXPERIMENTAL): Female participants with HER2-positive breast cancer will receive Herceptin 6 mg/kg IV on Day 1.
- Part 1: Cohort 3 (Type: EXPERIMENTAL): Healthy male participants will receive Herceptin 6 mg/kg SC on Day 1.
- Part 1: Cohort 4 (Type: EXPERIMENTAL): Healthy male participants will receive Herceptin 10 mg/kg SC on Day 1.
- Part 1: Cohort 5 (Type: EXPERIMENTAL): Healthy male participants will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohorts 1, 2, 3, and 4.
- Part 2: Cohort A (Type: EXPERIMENTAL): Female participants with HER2-positive breast cancer will receive Herceptin SC at the dose level determined in Part 1.
- Part 2: Cohort B (Type: EXPERIMENTAL): Female participants with HER2-positive breast cancer will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohort A.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quadratus Lumborum Block Versus Control for Total Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients undergoing total hip arthroplasty~2. Adults 18 years of age and older~3. Patients with an American Society of Anesthesiology (ASA) physical status classification of I, II or III~Exclusion Criteria:~1. Patients with ASA physical status classification other than I, II, or III~2. Patients with allergies/intolerances to local anesthetic~3. Patients with pre-existing neurologic or anatomic deficits in the lower extremity on the side of the surgical site~4. Patients with coexisting coagulopathy~5. Patients that are pharmacologically anticoagulated will be excluded if placement of peripheral nerve block would be contraindicated according to ASRA (American Society for Regional Anesthesia) guidelines or if spinal anesthesia would be contraindicated according to guidelines

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- quadratus lumborum block (QLB) (Type: EXPERIMENTAL): * Patients will be placed in the lateral decubitus position w/non-operative side recumbent. Pillow or blankets will be placed btw patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.~* Standard skin sterilization, prepping and draping will be applied to the area. Under ultrasound guidance, needle will be advanced to anterior border of quadratus lumborum muscle. After negative aspiration, a bolus of 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots.~* After QLB is placed, patients will have THA under spinal anesthesia.
- Standard of Care (Type: ACTIVE_COMPARATOR): * Patients will be placed in the lateral decubitus position with non-operative side recumbent. A pillow or blankets placed between patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.~* Standard skin sterilization, prepping and draping applied to the area. Ultrasound probe used to identify quadratus lumborum muscle. No local anesthetic injected.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Known Diabetes mellitus \> 6 months~* Increased Nt-proBNP above 125pg/ml~* Given informed consent~Exclusion Criteria:~* Disease other than diabetes, with a life expectancy below 1 year~* patients who suffer from chronic infection or malignant disease~* Women in childbearing age without contraceptive~* History of cardiac disease~* systemic cortisone treatment~* patients who are on chronic or acute hemodialysis, ultra filtration or peritoneal dialysis

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Patient will receive cardiac therapy to decrease NT-proBNP levels. This will be primarily RAAS-Antagonists and Betablocker. Blood pressure will be lowered to target values. A decrease of NT-proBNP is also known form life-style changes. Thus the patient will be educated to be trained
- 2 (Type: PLACEBO_COMPARATOR): Patients will be followed 2 years. Care will be given by the responsible unit ( Dept.of Endocrinology) as clinical appropriate. Event rates will be obtained. After one year NT-proBNP will be measured.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 18 years of age or older~* History of migraine with or without aura for more than 1 year with 1-8 moderate or severe migraine attacks per month in the 2 months prior to starting in the study~* Willing to stay awake for at least 2 hours after taking study drug~* Able to read, understand and complete questionnaires and diaries~Exclusion Criteria:~* Breast-feeding, pregnant, or plan to become pregnant during the study~* Not able to tell migraine attack from other headaches~* Older than 50 years of age at migraine onset~* Have more than 15 headache days per month or have taken medication for acute headache on more than 10 days per month in any of the 3 months before starting in the study~* History of gastric or small intestinal surgery~* History of heart attack, stroke, unstable angina, coronary artery bypass surgery or transient ischemic attack in the 3 months before starting in the study~* Currently participating or have participated in a study with in investigational compound or device in the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine
- Telcagepant 280 mg +Ibuprofen 400 mg (Type: EXPERIMENTAL): Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine
- Telcagepant 280 mg +APAP 1000 mg (Type: EXPERIMENTAL): Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine
- Telcagepant 280 mg (Type: PLACEBO_COMPARATOR): Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MyHand: An Active Hand Orthosis for Stroke Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects over 18 years of age~* History of stroke resulting in significant upper limb impairment~* Full passive range of motion~* Gross control of the proximal upper extremity~* Lacks timely grasp/release~* No more than moderate flexor tone~* Intact cognition~Exclusion criteria include:~* Other Neurological/orthopedic disorders~* Excessive spasticity/contracture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MyHand orthosis (Type: EXPERIMENTAL): Subjects are trained to control and use the MyHand orthosis either with a shoulder harness or an electromyography (EMG) band. The MyHand orthosis aims to aid in fine motor skills such as picking up and holding items of varying shape, size and weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does Fluid Requirement Decrease With the Use of Pneumatic Compression Device on Lower Limbs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA(American Society of Anaesthesiologists) grade I or II, of both genders~* Age group of 25 to 50 years~* Patients undergoing surgeries under GA(General Anaesthesia) for 2-3 hours~Exclusion Criteria:~* Patients expected to get major blood loss~* Burns patients.~* Patients with significant cardiac diseases.~* Patients with pulmonary diseases and impaired renal function.~* Lower limb surgeries and abdominal surgeries

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: NO_INTERVENTION): No intervention was done ,served as a control group.
- Group B (Type: EXPERIMENTAL): Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion:≥ 18 years of age~* Treated with maintenance hemodialysis - PTH ≥ 300 pg/mL (31.8 pmol/L)~* serum calcium ≥ 8.4mg/dL (2.1 mmol/L)~* Ca x P ≥ 45 mg2\*/dL2 (3.63 mmol2/L2)~Exclusion Criteria: - Exclusion:~* Parathyroidectomy in the 12 weeks before the date of informed consent~* Received therapy with cinacalcet within 3 months of randomization~* Hospitalization within 12 weeks of randomization for any of the following events: a. Myocardial ischemia b. Unstable angina c. Heart Failure (HF) (including any unplanned presentation to a health care facility that would require mechanical intervention \[i.e., unplanned dialysis treatment\]) d. Peripheral vascular disease (other than dialysis vascular access revision) e. Stroke~* History of seizure within 12 weeks prior to randomization~* Scheduled date for kidney transplant from a known living donor~* Anticipated parathyroidectomy within 6 months after randomization~  * in all instances, the 2 refers to squared.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cinacalcet (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Online Yoga for Individuals With Mood Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Fluent in English~* Over age 18~* Self-report of having experienced depression, mania, or hypomania in their lifetime~Exclusion Criteria:~* Any contraindication to exercise (e.g., pregnant, physical injuries or any other reason prohibiting exercise).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Yoga class (Type: OTHER): A 30 minute online Hatha yoga video intervention will be administered to participants.Participants will only participate in one yoga class and complete follow-up questionnaires.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study for the Treatment of Diabetic Peripheral Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with pain due to bilateral peripheral neuropathy induced by type 1 or 2 diabetes mellitus. The pain must have been present for at least 6 months and be evaluable in feet, legs, or hands.~* Participants with hemoglobin A1c (HbA1c) less than or equal to 9.0 percent at Visit 1.~* Participants in whom HbA1c had been measured 42-70 days before Visit 1 and subsequent HbA1c levels have been within +/- 1.0 percent of the level at Visit 1.~* Participants with a mean of the 24-hour average pain severity scores (round off to a whole number) of 4 or higher, as calculated from the patient diary for 7 days immediately before Visit 2~Exclusion Criteria:~* Participants who have undergone renal transplant or who are currently on renal dialysis.~* Participants who have a history requiring pharmacotherapy within the past year or current history of psychiatric disease, such as mania, bipolar disorder, depression, anxiety disorder, or eating disorder.~* Participants with hypertension with poor control of blood pressure (systolic blood pressure greater than or equal to 180 millimeters of mercury (mmHg) or diastolic blood pressure greater than or equal to 110 mmHg~* Participants with alanine transaminase (ALT) or aspartate transaminase (AST) greater than or equal to 100 Units per Liter (U/L) at Visit 1.~* Participants unable to discontinue prohibited concomitant drugs or concomitant therapies after Visit 1.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Duloxetine 60 (Type: EXPERIMENTAL): duloxetine 60 milligram (mg) taken orally every day
- Duloxetine 40 (Type: EXPERIMENTAL): Duloxetine 40 mg taken orally every day
- Placebo (Type: PLACEBO_COMPARATOR): placebo comparator taken orally every day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Parent/legal acceptable representative is willing and able to understand the protocol requirements and provide informed consent.~* Participant is aged ≥ 60 days to ≤ 75 days.~* Participant without preventive inoculation of polio vaccine and previous history of Polio.~* Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures.~* Body temperature ≤ 37.5℃.~Exclusion Criteria:~* Known allergy to any constituent of the vaccine.~* Known acute illness, severe chronic disease, acute exacerbation of chronic disease and fever.~* Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth.~* Reported the history of allergies, convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction.~* Known bleeding disorder.~* Receipt of the whole blood, blood plasma or immunoglobulin before the trial vaccination.~* Reported the history of acute illness had need systemic antibiotics or antiviral treatment of infections in the 7 days preceding the trial vaccination.~* An acute illness with or without fever (temperature ≥ 38.0℃) in the 3 days preceding enrollment in the trial.~* Participation in any other intervention clinical trial.~* Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the vaccine.

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 75 Days
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): The sequential immunization strategy for group 1 on polio was Sabin IPV+ bOPV + bOPV.
- Group 2 (Type: EXPERIMENTAL): The sequential immunization strategy for group 2 on polio was Sabin IPV + Sabin IPV + bOPV.
- Group 3 (Type: EXPERIMENTAL): The sequential immunization strategy for group 3 on polio was Sabin IPV + Sabin IPV + Sabin IPV.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete